Earnings Releases·Nov 10, 2026, 7:25 AM ET

Cellectar Biosciences — Third Quarter 2026 Earnings Summary

Cash and cash equivalents increased to $24.6 million as of September 30, 2026, from $13.2 million at year-end 2025 following $31.7 million in net proceeds from a May 2026 offering, extending funding runway into Q2 2027.
Net loss for the three months ended September 30, 2026, was $8.0 million ($0.46 per share), compared to $4.4 million ($1.41 per share) in the prior year period, driven by a rise in R&D expenses to $5.4 million from $2.5 million.
The company remains on track to dose the first patients in the confirmatory Phase 3 trial of iopofosine I 131 in Q1 2027, with a New Drug Application (NDA) for accelerated FDA approval planned for the first half of 2027.
Management highlighted strong Phase 2b CLOVER-WaM data for iopofosine I 131 showing an 87.5% Overall Response Rate in post-BTK inhibitor patients and confirmed enrollment continues for the CLR 125 Phase 1b trial in triple-negative breast cancer.